

Not for release, or for publication or distribution, directly or indirectly in or into the United States, Australia, Hong Kong, Canada, Japan, New Zealand or South Africa.

PRESS RELEASE
9 March 2012



Extraordinary General Meeting approved rights issue

Lund, Sweden – 9 March 2012 – Today's extraordinary general meeting in BioInvent International AB (publ) (OMXS: BINV) approved the Board of Director's decision to carry out a directed new share issue with preferential right for the shareholders of the company.

The rights issue will increase the share capital of BioInvent by a maximum of SEK 3,360,262.50 through the issuance of not more than 6,720,525 new shares. The company's shareholders will have preferential rights to subscribe for the new shares in proportion to the number of shares previously held by them. The record date for participation in the rights issue is 14 March 2012. Those who are registered as shareholders in BioInvent on the record date may subscribe for one (1) new share for each ten (10) existing shares in BioInvent. The subscription period runs from 16 March 2012 up to and including 30 March 2012 or such later date as the Board of Directors may decide. The subscription price is SEK 15.60 per share, which means that the rights issue will raise BioInvent a total of up to SEK 104,8 million before transaction costs.

For further information, please refer to the press release made public on 14 January 2010 in relation to the Board of Director's decision.

--END--

To the editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

For further information, please contact:

BioInvent International AB

Svein Mathisen
President & CEO
Phone: +46 (0)46 286 85 67

Sten Westerberg
Vice President, Investor Relations
Phone: +46 (0)46 286 85 52

Mobile: +46 (0)708 97 82 13
E-mail: [svein.mathisen@bioinvent.com](mailto: svein.mathisen@bioinvent.com)

Mobile: +46 (0)768 68 50 09
E-mail: [sten.westerberg@bioinvent.com](mailto: sten.westerberg@bioinvent.com)

BioInvent International AB (publ)

Co. reg. No. 556537-7263,
Address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Tel: +46 (0)46 286 85 50
[info@bioinvent.com](mailto: info@bioinvent.com)
[www.bioinvent.com](http: // www.bioinvent.com)

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act. The information was submitted for publication at 11.30 a.m. CET, on 9 March 2012.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in BioInvent International AB. Any invitation to the persons concerned to subscribe for shares in BioInvent will only be made through the prospectus that BioInvent estimates to publish on or about 14 March 2012.

This press release may not be published or distributed, directly or indirectly in or into the United States, Australia, Hong Kong, Canada, Japan, New Zealand, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares will be registered under the United States Securities Act of 1933 ("**Securities Act**") or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.

This press release may contain forward-looking statements which reflect BioInvent's current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the real outcome could differ materially from the forward-looking statements.